Back

Medicus Pharma shifts SkinJect development to Gorlin syndrome patients

Verifying
  • Medicus Pharma will focus SkinJect on Gorlin syndrome patients with multiple basal cell carcinoma lesions.
  • $25,800 modeled net price per treatment supported a $1.1 billion U.S. addressable market.
  • FDA placed Medicus’s two designation requests on hold pending additional information.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.